Covid-19 Flagship Project
In partnership with the OTAVA Ltd, our software has designed promising, novel antiviral medicines to combat Covid-19 which had promising In- Vitro Results.
Specifically, these drug candidates target the PLPro receptor, a key protein involved in the reproduction of the Coronavirus, opening a new door of opportunity to how we combat the pandemic. More information about the testing done to these molecules con be found in our BioRXV publication linked below
Academic Collaborations
Dr. Julio Agnetti and Dr. Thomas Lectka With Johns Hopkins University
Beginning with designing multiple treatments for Heart Disease with Dr. Agnetti, JHU added on for a project for Lipidemia with Dr. Leckta/Carnegie Institute (both projects bringing their molecules into the lab), with collaborative efforts for other diseases with John Hopkins researchers on the way.
University of California Irvine
Designing treatments for multiple neurological disorders, starting with Huntington’s Disease. The Huntington’s candidates are currently undergoing lab testing
.University of Kentucky
Designing treatments for breast cancer. Breast Cancer candidates are currently undergoing lab tests.
Dr. Wayne Childers with
Temple University
Designing Inhibitors for the PI3Ka cancer targets, that influence breast and ovarian cancers. So far Dr. Childers candidates have had great success in IC50 tests.
University of California San Diego
Designing treatments for Alzhiemer’s
Corporate Collaborations
Otava LTD
Helped design/synthesize our flagship drug candidates for the Covid-19 PLPro receptor.
*Use of the above logos represents an active or pending collaboration with the organization and does not signify any official endorsement of Phronesis Artificial Intelligence, Inc.*